TRUST

Multi-modal effects of thyroid hormone replacement for untreated older adults with subclinical hypothyroidism; a randomised placebo-controlled trial

Coordinatore	UNIVERSITY OF GLASGOW    more  Organization address address: University Avenue city: GLASGOW postcode: G12 8QQ contact info Titolo: Prof. Nome: David J Cognome: Stott Email: send email Telefono: +44 141 211 4976
Nazionalità Coordinatore	United Kingdom [UK]
Sito del progetto	http://www.trustthyroidtrial.com/
Totale costo	7˙764˙598 €
EC contributo	5˙963˙787 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2011-two-stage
Funding Scheme	CP-FP
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-11-01   -   2016-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY OF GLASGOW  Organization address address: University Avenue city: GLASGOW postcode: G12 8QQ contact info Titolo: Prof. Nome: David J Cognome: Stott Email: send email Telefono: +44 141 211 4976	UK (GLASGOW)	coordinator	2˙329˙422.80
2	UNIVERSITAET BERN  Organization address address: Hochschulstrasse 4 city: BERN postcode: 3012 contact info Titolo: Ms. Nome: Maddalena Cognome: Tognola Email: send email Telefono: +41 31 6314809 Fax: +41 31 6315106	CH (BERN)	participant	1˙316˙579.60
3	UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK  Organization address address: Western Road city: CORK postcode: - contact info Titolo: Dr. Nome: David Cognome: O'connell Email: send email Telefono: +353 21 490 3501 Fax: +353 21 490 3506	IE (CORK)	participant	1˙111˙161.60
4	ACADEMISCH ZIEKENHUIS LEIDEN  Organization address address: Albinusdreef 2 city: LEIDEN postcode: 2333 ZA contact info Titolo: Prof. Nome: Jacobijn Cognome: Gussekloo Email: send email Telefono: +3171526 8444	NL (LEIDEN)	participant	1˙106˙622.00
5	LEYDEN ACADEMY ON VITALITY AND AGEING  Organization address address: RIJNSBURGERWEG POORTGB K 10 city: LEIDEN postcode: 2333AA contact info Titolo: Prof. Nome: Rudi Cognome: Westendorp Email: send email Telefono: 31715240960	NL (LEIDEN)	participant	100˙001.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Subclinical hypothyroidism (SCH) is a common condition (8-18%) among European older men and women. Although by definition SCH comprises biochemically mild thyroid hormone deficiency without overt symptoms, it is a likely contributor to multiple problems in older age. Thyroid hormone has multiple pleiotropic effects on numerous physiological systems, including the vascular tree, heart, skeletal muscle and brain. Therefore, thyroxine substitution to overcome thyroid hormone deficiency has the potential to give multi-system benefits to older people with SCH. Small studies have reported reduced atherosclerosis and improved cardiac function with thyroxine replacement, but no large clinical trials have been performed. Therefore the available evidence is limited, leading to major variations in guidelines and clinical practice, with uncertainty regarding the indications for screening and treatment. We propose a multicentre randomised placebo-controlled trial to assess the impact of thyroxine replacement in 3,000 older adults with persisting SCH (excluding those in whom it is a temporary phenomenon who are less likely to benefit). We will include older men and women with a wide age range and of varying health status. Outcomes include cardiovascular events, health-related quality of life, muscle strength and executive cognitive function over 3-years of follow-up. We have the support of patient advocacy groups and a consortium with the wide range of expertise and experience required to conduct large-scale multicentre clinical trials. The proposal fits with the call, exploring the multi-system and quality-of-life benefits to older people of a tailored approach to management of SCH. This clinical trial should definitively clarify whether thyroxine treatment for SCH provides benefits that are relevant for patients. This trial will provide strong evidence with the potential to improve clinical practice, reduce healthcare costs and promote healthy ageing of European older adults.'